Metformin/ja: Difference between revisions
Metformin/ja
Created page with "<!-- Chemical and physical data --> | IUPAC_name = ''N'',''N''-Dimethylimidodicarbonimidic diamide | C = 4 | H = 11 | N = 5 | SMILES = CN(C)C(=N)N=C(N)N | StdInChI = 1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8) | StdInChI_comment = | StdInChIKey = XZWYZXLIPXDOLR-UHFFFAOYSA-N | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | density = 1.3±0.1 | density_notes = | melting_point = | melting_high..." |
Created page with "== 外部リンク == {{Commons category|Metformin}} * {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }}" |
||
| Line 524: | Line 524: | ||
</div> | </div> | ||
| |||
== さらに読む == | |||
{{refbegin}} | {{refbegin}} | ||
* {{cite journal | vauthors = Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J | title = Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics | journal = Current Pharmaceutical Design | volume = 23 | issue = 17 | pages = 2532–2550 | date = 2017 | pmid = 27908266 | doi = 10.2174/1381612822666161201152941 }} | * {{cite journal | vauthors = Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J | title = Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics | journal = Current Pharmaceutical Design | volume = 23 | issue = 17 | pages = 2532–2550 | date = 2017 | pmid = 27908266 | doi = 10.2174/1381612822666161201152941 }} | ||
| Line 540: | Line 536: | ||
* {{cite journal | vauthors = Zhou T, Xu X, Du M, Zhao T, Wang J | title = A preclinical overview of metformin for the treatment of type 2 diabetes | journal = Biomedicine & Pharmacotherapy | volume = 106 | pages = 1227–1235 | date = October 2018 | pmid = 30119191 | doi = 10.1016/j.biopha.2018.07.085 | s2cid = 52031602 }} | * {{cite journal | vauthors = Zhou T, Xu X, Du M, Zhao T, Wang J | title = A preclinical overview of metformin for the treatment of type 2 diabetes | journal = Biomedicine & Pharmacotherapy | volume = 106 | pages = 1227–1235 | date = October 2018 | pmid = 30119191 | doi = 10.1016/j.biopha.2018.07.085 | s2cid = 52031602 }} | ||
{{refend}} | {{refend}} | ||
== 外部リンク == | |||
{{Commons category|Metformin}} | {{Commons category|Metformin}} | ||
* {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | * {{cite web | title=Nitrosamine impurities in medications: Guidance | website=Health Canada | date=4 April 2022 | url=https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/nitrosamine-impurities/medications-guidance.html }} | ||
{{Merck Serono|state=autocollapse}} | {{Merck Serono|state=autocollapse}} | ||
{{Oral hypoglycemics and insulin analogs|state=collapsed}} | {{Oral hypoglycemics and insulin analogs|state=collapsed}} | ||
{{Portal bar | Medicine}} | {{Portal bar | Medicine}} | ||
[[Category:Biguanides]] | [[Category:Biguanides]] | ||